Abdunoor Mulokozi Kabanywanyi

In the News

Study establishes link between gender, extramarital affairs and HIV

Dar es Salaam. A new Ifakara Health Institute study has found “a significant association between lifetime (proxy) extramarital affairs and HIV infection among women only,” with the risk being significantly …

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Abdunoor Mulokozi Kabanywanyi

Research Scientist

Dr. Abdunoor Mulokozi Kabanywanyi is a principal researcher and clinical epidemiologist at Ifakara Health Institute. He is a medical doctor and holds MSc and PhD in clinical epidemiology from the University of Rotterdam in the Netherlands and Basel in Switzerland respectively. He joined Ifakara health Institute in 2001, where since then he has worked as a clinical researcher. Dr Mulokozi has researched mostly on anti-malarial drugs and tropical neglected diseases. He has implemented Clinical trials ranging from early phases to field epidemiology research and Pharmacovigilance. He provides medical care to patients, he also teaches and has published in the area of malaria drugs. Dr Mulokozi is currently working on two research projects; 1) Safety of artemisinin based combination therapy in Tanzania, and 2) A phase I palatability trial of plazquantel new formulation in African young school children. Dr Mulokozi plans to extend his research on malaria in pregnancy, over the next four years, 2017-2020.

View Dr. Kabanywanyi’s Research Interests and Publications

Projects

No items found
A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016